( ine-refractory or not suitable candida...)New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy,Health

ine-refractory, or not suitable candidates for iodine treatment. This showed an objective response rate with axitinib of 30 percent. 72 percent of patients received a clinical benefit, meaning a partial response or stable disease was observed (partial response 30 percent and 42 percent with stable disease greater than or equal to 16 weeks). Treatment duration range was 6-744 days, with 24 patients currently still on treatment.

A global trial of axitinib in advanced refractory thyroid cancer patients, who have become resistant to a commonly used chemotherapy, is ongoing.

Metastatic Breast Cancer

A randomized, double-blind, placebo-controlled Phase II study found that axitinib combined with the chemotherapy docetaxel, demonstrated an acceptable safety profile and anti-tumor activity in the first-line treatment of metastatic breast cancer.

A total of 168 patients were randomized to receive docetaxel plus axitinib (AG) or docetaxel (DOC) plus placebo (PL). The median time to tumor progression (TTP) was 8.2 months in the AG + DOC arm versus 7 months in the DOC + PL arm (P=0.052). The objective response rate (ORR) was 40 percent for AG + DOC arm and 23 percent for DOC + PL arm (P=0.038).

Advanced Renal Cell Carcinoma (RCC)

A multicenter, open-label, Phase II study investigated axitinib in RCC patients with advanced RCC who were resistant to multi-kinase therapy. The study found that axitinib demonstrated anti-tumor activity in advanced RCC.

Of the 62 patients in the study, partial response was observed in 13 patients (21 percent) and 21 patients experienced stable disease (34 percent). Median Progression Free Survival (PFS) was 7.4 months.

Data from an open-label multi-center Phase II study of single-agent axitinib in non-small cell lung cancer were also presented this week.

"Pfizer is committed to delivering new and innovative options to patients living with cancer," said Charles Baum, MD PhD, head of oncolog
'"/>

Page: 1 2 3 4
Related medicine technology :

1. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
2. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
3. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
4. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
5. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
6. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
7. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
8. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients